{"prompt": "['CONFIDENTIAL', '204878 (ZOSTER-064)', 'Protocol Administrative Change 3 Final', 'with normative values for those questionnaires in the general population of the countries', 'participating in the study (where these values are available) will also provide further', 'insight in the study population and allow to better understand the study population', 'compared to the overall target population for the vaccine.', 'Analyses pertaining to efficacy, safety and immunogenicity as per frailty score might', 'then also be performed according to the methodology used in the ZOSTER-006 and', 'ZOSTER-022 studies.', 'Additionally, the data collected can be used to assess if some physical, physiological', 'and/or psychological characteristics reported by the subjects before the onset of HZ', 'would be predictive of HZ. This will help understand the previously hypothesized', 'predictive factors such as stress or functional status, and also to assess other potential risk', 'factors such as frailty, fatigue or emotional and mental health.', '2.', 'BENEFIT: RISK ASSESSMENT', 'ZOSTER-064 study will use data collected as part of the SF-36 and EQ-5D QoL', 'questionnaires completed by subjects in ZOSTER-006 and ZOSTER-022 studies. There', 'are no risks or benefits to subjects in this study because this is a retrospective', 'observational study.', '3.', 'OBJECTIVES', '3.1.', 'Primary Objective', 'To assess the baseline frailty of subjects enrolled in ZOSTER-006 and ZOSTER-', '022.', '3.2.', 'Secondary Objectives', 'To present the distribution of SF-36 and EQ-5D scores in subjects included in', 'ZOSTER-006 and ZOSTER-022 at baseline by country to allow comparison with', 'normative values for those questionnaires in the general population of the countries', 'participating in the study.', 'To assess vaccine efficacy against HZ by frailty status.', 'To assess HZ burden of illness (BOI) by frailty status.', 'To identify predictive factors for individuals developing HZ.', 'To describe safety per frailty status.', 'To assess humoral immunogenicity by frailty status.', '3.3.', 'Tertiary Objectives', 'To describe CMI by frailty status of subjects enrolled in ZOSTER-006 only.', '11-FEB-2019', '23', '70882527ffe6806e42bab9a20b06541da11028ce']['CONFIDENTIAL', '204878 (ZOSTER-064)', 'Protocol Administrative Change 3 Final', '4.', 'STUDY DESIGN OVERVIEW', 'Protocol waivers or exemptions are not allowed. Therefore, adherence to the study design', 'requirements, including those specified in the outline of study procedures (Section 8), are', 'essential and required for study conduct.', 'Type of design: Observational, retrospective study.', 'Study population: Adults aged >50 years of age who participated in either ZOSTER-', '006 or ZOSTER-022.', 'Type of study: to be combined with other protocols for analysis: data to be analysed', 'in this study have been collected in ZOSTER-006 (eTrack 110390) and ZOSTER-', '022 (eTrack 113077).', 'Data collection: CRF/eCRF', 'Duration of the study: The time between the first and the last information to be', 'encoded will be approximately 8 months.', '4.1.', 'Discussion of study design', 'This is a retrospective, observational study, therefore no new subjects will be enrolled in', 'this study and no new ICF will be required from study subjects (see Section 7.2). In', 'ZOSTER-006 and ZOSTER-022, encoding of QoL questionnaires (SF-36, EQ-5D) was', 'only performed for subjects who developed a suspected HZ episode during the study.', 'This was done to assess the QoL of subjects who developed suspected cases of HZ', 'between the vaccine group and the placebo group. The remaining study subjects who did', 'not develop suspected cases of HZ completed the questionnaires; however, these', 'questionnaires were never encoded or analysed as part of ZOSTER-006 and ZOSTER-', '022. The purpose of ZOSTER-064 is to allow for the encoding of the remaining', 'questionnaires to assess the baseline frailty of all the subjects in ZOSTER-006 and', 'ZOSTER-022.', '5.', 'HZ CASE DEFINITION', 'Classification as a HZ confirmed case was done during ZOSTER-006 and ZOSTER-022,', 'after confirmation of all suspected HZ cases by either of the two following ways:', 'Polymerase Chain Reaction (PCR):', 'Rash lesion samples were collected from subjects clinically diagnosed as having a', 'suspected case of HZ. The samples were transferred to GSK Biologicals or a', 'validated laboratory designated by GSK Biologicals using standardised and validated', 'procedures for laboratory diagnosis of HZ by PCR. For more information, please', 'refer to Appendix B of the ZOSTER-006 protocol.', 'The HZ Ascertainment Committee:', '11-FEB-2019', '24', '70882527ffe6806e42bab9a20b06541da11028c']\n\n###\n\n", "completion": "END"}